In the News

In acquiring PRA, ICON would expand into digital and technology capabilities that are playing roles in clinical trials accelerated by the Covid-19 pandemic, such as virtual monitoring of study subjects as people stay at home and avoid public places.

ICON will acquire PRA Health Sciences for $12 billion in a move that will shake up the hightest rungs of a fragmented market.

The combined company will form the world’s largest contract research organisation, and is to be headquartered at ICON’s Leopardstown campus in Dublin.

ICON acquires PRA Health Sciences to form a world-leader CRO.

ICON has announced one of the biggest takeover deals in Irish corporate history.

​ICON will buy PRA Health Sciences for about $12 billion in cash and stock, snapping up one of the larger independent companies in the drugmaker services business.

In a cash and stock transaction value of approximately $12 billion, ICON plc has announced its acquisition of PRA Health Sciences as part of a focus on innovative and high- quality clinical trials.

ICON is set to acquire rival PRA Health Sciences in a $12 billion deal that will vault the combined company into second place among clinical trial services providers.

In this article, EB McLindon offers insights to help sponsors decide which approach is most optimal for a clinical trial.

Dr. Caroline Forkin discusses the current status of HIV treatments and potential for researchers to develop a vaccine.